PHARMING GROUP Stock: Weekly Decline in a Generally Rising Market
This week, PHARMING GROUP's stock experienced a significant downturn, marking a negative performance while the main European indices generally showed an upward trend. The stock, known for its volatility, moved in a dynamic market environment, particularly supported by the strong performance of the CAC 40 stocks. This development contrasts with the trend observed over the past twelve months, during which the stock has significantly appreciated.
By the end of the trading week, PHARMING GROUP's stock had fallen by 7.12%, closing at €1.2010. This negative trend starkly contrasts with the rebound seen in the CAC 40 (+1.65%) and the SBF 120 (+1.35%) over the same period. Throughout the week, the stock price fluctuated between a low of €1.197 and a high of €1.284, showing significant volatility. The average capital turnover remained stable, reflecting regular activity on the stock without any particular spikes in volume. Over the last five sessions, the stock moved erratically, with a notable decline at the end of the week. Despite the weekly drop, the annual performance remains strong, standing at +53.58% over twelve months. However, the trend over the past month has been moderate, with a limited increase of 1.01%, indicating a slowdown after a strong growth phase in the second quarter. The current market dynamics also differ from those at the beginning of October, when the stock had appreciated by more than 4%. The overall market context, driven particularly by strong growth in certain sectors and positive news about several major stocks, was not enough to support PHARMING GROUP's trajectory this week. This underperformance occurs in a market environment that remains generally positive in October.
Technical Analysis
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
From a technical standpoint, the weekly close positions PHARMING GROUP just below its 20-day and 50-day moving averages, which are at €1.257 and €1.19 respectively. However, the stock is still above the 200-day moving average, set at €1.12, indicating a generally positive underlying trend over a broader horizon. The Bollinger Bands frame recent fluctuations with an upper bound at €1.35 and a lower bound at €1.16, showing a relatively controlled range of variation for the period. The RSI indicator is balanced around 50, indicating no extreme tension in the stock. Meanwhile, the MACD shows a main line at equilibrium, reflecting hesitation between continuing consolidation and attempting a short-term rebound. Finally, the weekly support threshold is at €1.13, while resistance is at €1.38, pivotal levels in case of more pronounced fluctuations in the upcoming sessions.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T3 2026
Key reported figures
Revenue: 117,6 millions de dollars
Quarterly revenue: 117,6 millions de dollars
Revenue growth: 21 %
Guidance from the release
Tightened 2026 total revenue guidance to between US$380 million and US$390 million from prior US$375 million to US$395 million
Risks mentioned
Joenja revenue growth was partly driven by temporary benefit from ordering patterns in other international markets
RUCONEST third quarter revenue includes an early seasonal increase in channel inventory at a single U.S. specialty pharmacy customer, following significant drawdowns earlier in the year
Napazimone (KL1333): enrollment in the pivotal FALCON trial now expected to complete in the first half of 2027 (about 145 of 180 subjects by end-2026), with topline results approximately one year after completion of enrollment
Opportunities identified
RUCONEST stabilization and continued recovery of demand in the US (third quarter revenue of about US$93.8 million, +14% year-on-year and +30% versus the second quarter of 2026)
Joenja strong growth driven by launches in Germany, Japan and continued penetration in the U.K.
Substantial growth potential for Joenja with estimated CVID with immune dysregulation prevalence of 39 patients per million vs 1.5 for APDS
Outlook / guidance
Expected revenue: 385 millions de dollars
Management commentary: Tightened 2026 total revenue guidance to between US$380 million and US$390 million (1% to 4% growth) from prior US$375 million to US$395 million (0% to 5% growth)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
